A win for Murray and a win for Regen Med. Last week the House of Lords Science and Technology Select Committee published its report on Regenerative Medicine which charts a way to commercialise cell therapy and regenerative medicine in the UK – an area where we know we have the capacity to be world class. Do take a look at the report. The Lordships’ recommendations for streamlining of the regulatory pathway for regenerative medicines and for government to explore innovative funding models can provide the spur that this developing sector of UK bioscience needs. It’s great that the Committee recognises that new financing models will help innovative UK businesses developing regenerative medicines and that the BIA’s proposed Citizens’ Innovation Funds could play a role. Chris Mason, Chair of our Cell Therapy and Regenerative Medicine Advisory Committee has provided his thoughts on the report and believes it is a call to action for the sector.

It’s a busy week of meetings for the UK biotech sector and I’m looking forward to seeing a record number of you and some new faces at our CEO and Investor Forum on Wednesday evening and Thursday. One Nucleus’ OnHelix translational research conference this Tuesday 9 July in Hinxton is set to be a great event too. And the UK synbio community is together this week at Imperial College for SB6.0 with many of our member companies presenting at SynBioBeta on Wednesday night (sorry I can’t be in two places at once). If all of this is a bit southern for you I’d suggest marking your diary now for 18 September when Bionow is holding its BioCap life science investment showcase conference in Manchester.